You are here:

Forthcoming Submission: cabazitaxel (Jevtana)

Indication: in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer (mHRPC) previously treated with a doxetaxel-containing regimen.

Drug Details

Drug Name: cabazitaxel (Jevtana)
Drug Manufacturer: Sanofi-Aventis
BNF Category:
Sub Category: 8.1 Cytotoxic drugs
Submission type: Full submission
Patient Interest Group
Submission Deadline:
29/02/2016
SMC Meeting Date: Q2 2016
Advice Due: Q2 2016

Back